Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
Open Access
- 1 December 1995
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 346 (8990), 1593-1596
- https://doi.org/10.1016/s0140-6736(95)91929-5
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Low‐dose combined oral contraceptivesBJOG: An International Journal of Obstetrics and Gynaecology, 1994
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- The natural history and epidemiology of venous thrombosisProgress in Cardiovascular Diseases, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- New progestogens in oral contraceptionContraception, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.BMJ, 1993
- Oral contraceptives and venous thromboembolism: findings in a large prospective study.BMJ, 1986
- ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE: EFFECTS OF LOWERING ŒSTROGEN CONTENTThe Lancet, 1980
- ORAL-CONTRACEPTIVE USE IN RELATION TO MYOCARDIAL INFARCTIONThe Lancet, 1979